
price close busi june
domin global leader next
gener sequenc instrument
biomed devic servic
despit near-term risk remain
epicent variou wave precis medicin
takeaway road
recent privileg host illumina cfo ad vice-president ir jacqui
ross two day investor meet less human ever
sequenc less variant human genom fulli
character see multi-year path growth ahead research clinic
sequenc near-term risk linger close acquisit summer
acceler ramp revenu success deploy pop gen project
recoveri direct-to-consum dtc genet test confid demand
high-margin sequenc consum intact believ
year commit spend coupl best-in-class peopl enabl
maintain leadership posit year reiter buy rais pt
cancer profil big growth driver seen larg custom like
buy-rat liquid biopsi tumor profil
foundat tempu cari expect tumor profil growth acceler pend
expans medicar coverag liquid biopsi pan-canc
average-risk nipt acog bulletin hope week power liquid
biopsi custom instrument consum believ investor
underappreci initi develop trusight oncolog assay beyond
ffpe offer look launch panel also blood
good line sight popul genom seem like investor
concern guid revenue ramp vs pop
genom initi meet indic good line sight
global program track account
ramp peg sampl us million veteran program
genom england phase franc australia singapor project
dtc mysteri high level specul futur dtc
custom could launch tier offer could includ sequenc array
specul year believ want counter
critic lack clinic util health result need move
sequenc health offer think need address privaci
concern think whether want offer genet counsel line
think correct may requir addit develop regulatori time
thu put growth rate us dtc test risk view
thu us dtc recoveri may occur instead may creat
headwind orasur labcorb view said think temporari
slowdown array forgiven beat high-margin sequenc consum
continu expect close acquisit pacbio summer
chang phase dialogu uk phase ftc us
indic deal closur progress plan peg chanc
deal approv summer note deal spread widen
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact inform appear front page report
buy unchang target price june
biomed devic servic
buy unchang target price june
biomed devic servic
buy unchang target price june
biomed devic servic
buy unchang target price june
biomed devic servic
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti llc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin june et
date time product june et
pt use multipl adj ep estim
pt use multipl revenu estim million discount back year discount rate use
dilut share outstand model revenu growth y/i ep gross margin oper
margin
laboratori corpor america hold lh
pt use multipl adj ep estim
pt use multipl revenu estim discount back two year discount rate
price target base use multipl revenu estim discount back two year
discount rate ad net cash posit balanc sheet
risk achiev target price valuat
believ key risk includ major new product launch novaseq instrument premium valuat excess
peer group risk associ demand pace novaseq placement hiseq unit decommiss
competit noise/tract though believ meaning competit risk well bay nih/govern budgets/
spend particularli foreign govern like japan genom research center regulatori risk fda addit
risk factor less concern includ typic medic technolog risk price instrument consum risk
associ move test clinic increas compani focu bioinformat long-term also
highlight spend scale helix
premium valuat gh trade premium multipl rel mani diagnost compani given gh best class liquid
biopsi portfolio huge believ valuat warrant bad news regulatori reimburs time product
launch shortfal financi could result lower move stock
risk obtain fda approv flagship test pan-canc label current ldt
gh take assay fda expedit access pathway via breakthrough devic design eap design
expect give prioriti review access senior fda offici doesnt guarante approv guardant view fda approv
signific mileston need facilit commerci adopt extend approv timelin would pose risk
risk obtain pan-canc medicar coverag today gh medicar coverag nsclc guardant
expect obtain pan-canc medicar coverag base expect fda approv guardant expect nation
buy unchang target price june
biomed devic servic
coverag determin ncd test delay obtain pan-canc coverag would limit compani opportun
risk obtain fda approv guardantomni guardant recent launch guardant omni research use intend
take guardantomni fda obtain fda approv delay time rel expect could limit
compani opportun revenu
manag execut risk given technic natur develop liquid biopsi gh commerci success depend
manag abil launch new panel secur addit reimburs regulatori new label win
provid guidanc shortfal rel guid mark materi risk
risk launch commerci compani largest market opportun gh peg market opportun
high risk individu huge opportun primarili requir strong data gh releas promis pilot
data rel small sampl size guardant experi setback poor result delay/cancel launch
gh growth potenti would significantli reduc
competit guardant compet directli compani provid comprehens genom profil therapi select
foundat medicin roch think guardant like compet recurr monitoring/residu diseas
market among other guardant may compet screen diagnost compani includ
colorect cancer screen possibl grail launch
reimburs risk end cover live think fda approv like drive
broader payor adopt larg health insur aet other current coverag decis guardant
fail increas reimburs coverag would limit opportun
risk relat intern expans guardant offer test countri outsid establish
amea softbank facilit expans asia middl east africa engag clinic trial work japan lack
compel data regulatori setback could delay expans plan ou addit guardant could struggl facilit adopt
emerg market due pricing/reimburs test
relianc sole supplier guardant reli heavili sole sequenc provid gh activ suppli agreement
decemb automat renew thereaft contract either parti option opt agreement
notic year advanc opt gh may struggl find replac sequenc meet perform
risk relat oper larg grow lab san francisco bay area home earthquak san francisco bay area
prone earthquak larg earthquak could interrupt lab oper compani lab headquart redwood citi ca
laboratori corpor america hold lh
labcorp integr covanc macroeconom weak may threaten volum margin unemploy rate
hover around variou macroeconom headwind potenti reduc demand diagnost servic especi drugs-
of-abus doa pre-employ test rel cyclic busi segment roughli volum revenu
healthcar reform may lead medicar reimburs cut labcorp deriv revenu medicar medicaid
program lab industri provid face risk declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost believ all-in medicar reimburs rate lab increas
modestli expect medicar reimburs declin approxim labcorp face competit threat
could slow growth labcorp compet industri leader quest diagnost along numer smaller independ nich
clinic laboratori quest slightli larger scale scope labcorp smaller competitor may prove nimbl
innov labcorp australian-bas sonic healthcar build signific presenc
compet labcorp acquisit northeast lh compet bio-refer lab compani deriv
revenu higher-margin esoter test negoti health plan plan includ manag care organ
health insur provid repres approxim compani volum revenu compani largest health
plan exclus contract end repres approxim revenu estim
labcorp compet aggress quest contract health plan larg price margin contract length
panorama asp compress erod margin gross margin drop sequenti expect
margin continu erod result reduct in-network price commerci payor come on-line
expand includ averag risk patient expect mitig revenu impact asp compress drive
busi profit account though busi may suffer increas test volum outpac asp
relianc lab partner move away lab partner priorit direct sale continu sell
number refer lab partner includ arup clarient sonic unclear durabl compani lab partnership may
particularli sinc lost lab partner past certain lab choos promot anoth nipt decid offer
nipt includ recent quest
fda oversight ldt test lab-develop test ivd fda take posit author
regul test medic devic fdc act gener chosen enforc author mandat certain
ltd seek fda clearanc howev fda look regul ldt use risk-bas approach begin deem
buy unchang target price june
biomed devic servic
highest-risk devic follow lower risk devic believ panorama would treat moderate-risk high-risk
among highest-risk devic fda indic high-and moderate-risk ltd market
guidelin final remain market fda review submiss expect requir
remov product market regul fda ltd remain subject uncertainti controversi
constel addit talk fda receiv clearanc constel us fda indic
constel platform may appropri review de novo classif allow market
distribut constel us convers on-going fda requir obtain regulatori clearanc
market constel softwar diagnost purpos abl secur fda clearanc compli
on-going fda regulatori requir would unabl commerci constel compani cloud-bas distribut
competit compet directli compani offer nipt carrier screen test ob/gyn mfm
market labcorp roch counsyl mani compani larger abl
leverag economi scale win busi offer multipl test servic women health one requisit form
observ research doctor often switch test brand may make market share gain difficult
strong competit oncolog uncertain time oncolog launch develop liquid biopsi test oncolog
manag size opportun billion initi sampl collect activ lung ovarian
cancer collect dozen collabor includ vanderbilt stanford columbia cancer research uk
other also initi collect effort breast cancer plan announc collabor later year
alon pursu blood-bas test oncolog market leader today substanti base revenu data
counsyl trovagen pathway genom mdx name hand
ethic legal social concern relat genet inform could reduc demand genet test test provid
dna test servic like conduct use panorama expect conduct oncolog may rais ethic legal
social issu regard privaci appropri use result inform government author could social
purpos limit regul use genom inform genom test prohibit test genet predisposit certain
condit particularli known cure similarli concern may lead patient refus use genet test even
permiss ethic social concern may also complic abil protect patent technolog
import medicaid nipt approxim birth unit state state medicaid program recipi
end recogn medicaid provid state state requir compani oper lab
state becom recogn medicaid provid typic medicaid rate price medicar commonli lowest payor
term dollar
regulatori risk exist new test indic delay denial approv would neg affect compani commerci risk
exist product reimburs competit continu weak economi could inhibit growth orasur drug
abus test busi risk associ intern sale infecti diseas product risk relat fund hiv
particularli unit state competit risk gener hiv product dna genotek subsidiari larg
custom failur continu work would advers impact busi
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
buy unchang target price june
biomed devic servic
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
